Vaxcyte is a clinical-stage vaccine company developing broader-coverage pneumococcal conjugate vaccines. Its approach uses a cell-free protein synthesis platform intended to enable more serotypes than traditional conjugate methods. Lead candidates target prevention of invasive pneumococcal disease in adults and children; commercial revenue is not yet material.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -166.6 | — |
| Q3 2025 | 0 | — | -212.8 | — |
| Q4 2025 | 0 | — | -246.5 | — |
| Q1 2026 | 0 | — | -320.6 | — |
| Q2 2026 | 0 | — | -284.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Crinetics Pharmaceuticals, Inc. (CRNX), Viavi Solutions Inc. (VIAV), American Airlines Group Inc. (AAL), Paylocity Holding Corporation (PCTY), Bruker Corporation (BRKR), Legence Corp. (LGN)